Public Sector Prenosis has secured a $20M BARDA contract and recognition from HHS, signaling strong government validation and potential for expanded federal partnerships. These engagements create a pathway to deploy precision medicine platform and AI-enabled companion diagnostics within US national preparedness and emergency response programs.

Clinical Adoption FDA-authorized Sepsis ImmunoScore and ISO 13485 quality management position Prenosis as a credible clinical tool. This foundation supports conversations with hospitals, health systems, and payers about integration into clinical workflows and regulatory-compliant deployment.

AI Powered Diagnostics The company's AI-driven platform leverages holistic molecular and clinical data, enabling precision sepsis diagnostics and personalized therapy. This opens opportunities to partner with hospitals for implementation, collaborate with pharma for trial stratification, and license technology for other infectious disease indications.

Hospital Market The company has traction and recognition in the U.S. hospital market; opportunities exist to scale through system-wide deployments in large hospital networks and academic centers, supported by partnerships with GPOs and value-based care models.

Partnership Licensing Given FDA authorization, UL award, and recent funding, Prenosis is well positioned for licensing opportunities, co-development, or OEM-style partnerships with diagnostics vendors, labs, and pharma. This can accelerate go-to-market and scale beyond sepsis to other critical care indications.